The relevance of serum microRNAs in the diagnosis of prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003155

Enrollment

200

Registered

2011-06-22

Start date

2011-07-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61 N40

Interventions

Group 1: a serum sample will be collected from all patients prior prostate biopsy to analyse circulating miR-26a and PSA / %fPSA

Eligibility

Sex/Gender

Male

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: - indication of prostate biopsy according the S3-guideline prostate cancer, suspicion of prostate cancer (e.g. PSA elevation, abnormal digital-rectal examination, abnormal transrectal sonography) - age > 40 years - sex: male

Exclusion criteria

Exclusion criteria: history of secondary malignancy within the last 5 years

Design outcomes

Primary

Measure	Time frame
Analysis and comparison of the diagnostic accuracy of miR-26a, PSA and %fPSA	—

Secondary

Measure	Time frame
Difference of microRNA levels in differnet tumor stages	—

Countries

Germany

Contacts

Public ContactJörg Ellinger

Universitätsklinikum Bonn Klinik und Poliklinik für Urologie und Kinderurologie

joerg.ellinger@ukb.uni-bonn.de0228-28715109

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026